Anti-hIL-28a Neutralizing mAb

Neutralizing monoclonal antibody against human interleukin 28A

Neutralizing monoclonal antibody against human IL-28A

Anti-hIL-28a-IgG (clone 21C3) is a monoclonal antibody (mAb) for human interleukin 28A (hIL-28A). It is produced in hybridomas and purified by affinity chromatography. This antibody has been selected for its ability to efficiently neutralize the biological activity of hIL-28A. IL-28A (also known as interferon lambda 2) is a member of the type III interferon (IFN lambda) cytokine family that exhibits several common features with type I IFNs: antiviral activity and antitumor activity [1, 2]. 

More details

Key features:

• A potent neutralizing mAb against hIL-28A
• Provided azide-free
• Each lot is functionally tested

References:

1. Donnelly RP. & Kotenko SV., 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 30(8):555-64.
2. Li M. et al., 2009. Interferon-ls: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol., 86:23-32.

Figures

Anti-hIL-28a-IgG is a potent neutralization antibody. Increasing concentrations of Anti-hIL-28a-IgG were incubated for 30 minutes with the recombinant cytokine hIL-28a (1 ng/ml) prior to the addition of HEK-Blue™ IFN-λ cells. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are presented as percentage of neutralization (mean).

Specifications

Target: natural and recombinant human interleukin-28A (IL-28A)

Specificity: Reacts with human IL-28A and human IL-28B.
No cross-reactivity with mouse IL-28A or mouse IL-28B.

Clone: 21C3

Isotype: Mouse IgG1, kappa

Control: Mouse IgG1 Control

Immunogen: Human IL-28A protein expressed in Swiss mice following DNA immunization

Formulation: 0.2 µm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Tested applications: Blocking & Neutralisation

Quality control:

• This product has been validated for neutralization using cellular assays.
• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Contents

• 3 x 100 μg purified anti-hIL-28a-IgG antibody, provided azide-free and lyophilized

Product is shipped at room temperature.

Store lyophilized antibody at -20 °C.

Details

The IFN-λ family is essential to the antiviral response at epithelial barriers [1,2]. In humans, this family comprises four distinct proteins called IFN-λ1 (interleukin-29, IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and the poorly secreted IFN-λ4. In mice, two functional orthologs (IL-28A and IL-28B) have been described. IFN-λs are produced when a viral infection is sensed by pattern recognition receptors. IFN-λs bind to a heterodimeric receptor formed by the assembly of IFN lambda receptor 1 (IFNLR1) and IL-10 receptor beta (IL10Rβ). This leads to the recruitment of the Janus kinases, JAK1 and TyK2, and phosphorylation of STAT1 and STAT2, which then dimerize and interact with IFN regulatory factor 9 (IRF9), forming the ISGF3 complex. ISGF3 binds to IFN-stimulated response elements (ISRE) in the promoters of IFN-stimulated genes (ISG) to regulate their expression.

1. Lazear HM. et al., 2015. Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity. 43(1):15-28.
2. Lee S. & Baldridge MT., 2017. Interferon- Lambda: A Potent Regulator of Intestinal Viral Infections. Front Immunol. 8:749.